Over half of the cancer therapies Chinese companies out-licensed in 2021-22 employ new modalities or unapproved targets

Canaan-backed start-up is tapping T cell mobility, infiltration mechanisms to turn cold tumors hot

U.S.-based Pyxis takes rights to SIGLEC15 program that would trail NextCure’s candidate

Why SIGLECs are rising in the landscape of next-generation checkpoint targets

How four IPOs helped push YTD tally from public market debuts well ahead of last year’s pace.

Turning suppressive myeloid cells in tumors into immune-activating ones